BioSpace Editorial Staff

Biopharmas of varying sizes—including larger companies like Amgen, Gilead and Pfizer—cut employees in 2023 to stay afloat.
Despite recent layoffs and closures in the state, there are still many companies actively recruiting for roles in California.
In this special report, BioSpace examines how the biopharma industry is grappling with impending consequences of the Inflation Reduction Act.
Follow news from the American Society of Clinical Oncology 2023 annual meeting—BioSpace will be tracking key updates here throughout the conference.
BioSpace is proud to present its NextGen Bio “Class of 2023,” a list of the hottest recently launched life sciences companies in North America.
BioSpace’s 2023 “Best Places to Work,” highlights innovative companies with a positive workplace culture, flexibility and strong leadership.
A new municipal law took effect Tuesday in New York City, requiring companies with four or more employees to include a specific pay range in every job posting.
BioSpace is marking Martin Luther King, Jr. Day by sharing some of our recent coverage about what the life sciences industry is doing to address racial inequality.
Researchers in China are busy developing several treatments, combining vaccines and drugs for COVID-19, and also working on monoclonal antibodies treatment.
Parkinson’s disease has been immensely challenging for biotech companies. A high rate of late-stage attrition in trials has led to a lack of approved therapies for the disease.
During the past two years, fundraising and investment in biotechnology have reached record levels.
The growth of fibril tips is thought to be the ‘Achilles’ heel’ of the process.
In a recent multinational survey, healthcare providers expressed the belief that immunotherapy will improve outcomes for patients with earlier-stage cancers.
AI can enable the analysis of massive databases, accelerate research and development, save costs and promote effective decision making.
The analysis showed tezepelumab achieved an 86% reduction in the annualized asthma exacerbation rate with patients having nasal polyps, and 52% in patients not having nasal polyps.